Detalhe da pesquisa
1.
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
N Engl J Med
; 388(16): 1478-1490, 2023 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877098
2.
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
N Engl J Med
; 384(13): 1204-1215, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789009
3.
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Eur Respir J
; 61(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041750
4.
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
Eur Respir J
; 62(3)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696565
5.
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Ann Rheum Dis
; 79(5): 618-625, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299845
6.
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
Ann Rheum Dis
; 78(5): 648-656, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30852552
7.
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.
Ann Rheum Dis
; 78(9): 1242-1248, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31227488
8.
Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.
Rheumatology (Oxford)
; 57(5): 813-817, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415230
9.
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
Ann Rheum Dis
; 76(2): 422-426, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27457511
10.
SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
Circ Heart Fail
; 17(5): e011227, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572639
11.
The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
Clin Pharmacol Ther
; 115(3): 478-487, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38012534
12.
Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38812074
13.
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
Adv Ther
; 41(1): 130-151, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851297
14.
Patient perception of disease burden in diffuse cutaneous systemic sclerosis.
J Scleroderma Relat Disord
; 5(1): 66-76, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35382406
15.
Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR Study.
JACC Heart Fail
; 11(10): 1457-1459, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37452806
16.
[Ultrastructural and growth factor analysis of amniotic membrane preserved by different methods for ocular surgery]. / Análise ultraestrutural e de fatores de crescimento de diferentes métodos de preservação da membrana amniótica utilizada em cirurgia ocular.
Arq Bras Oftalmol
; 70(5): 756-62, 2007.
Artigo
em Português
| MEDLINE | ID: mdl-18157297
17.
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Respir Med
; 122 Suppl 1: S14-S17, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27746061